艾迪藥業(688488.SH):全資子公司獲得獲得珀金埃爾默HIV檢測試劑及儀器在中國大陸的總代理權
格隆匯12月20日丨艾迪藥業(688488.SH)公佈,公司全資子公司南京安賽萊醫藥科技有限公司與珀金埃爾默醫學診斷產品(上海)有限公司於2021年12月20日簽訂了《關於HIV診斷試劑及儀器總代理權的授權合同》,根據合同約定,艾迪藥業全資子公司獲得珀金埃爾默HIV檢測試劑及儀器在中國大陸地區(不含港澳台)的總代理權,授權期限為合同簽署生效日至2024年12月31日。
公司從“滿足國內艾滋病治療的迫切需求”戰略出發,正致力於踐行“HIV診療一體化”的理念,通過構建具有中國特色的集診斷、病載檢測、耐藥篩查、用藥建議、精準治療、病程管理等於一體的慢病管理體系,給予患者全生命週期的診療與關懷,提高患者體驗感、增加患者和醫生的信任度;珀金埃爾默專注感染診斷及輸血安全超過20年,同時也一直在探索感染性疾病的“診療一體化”方案;此次雙方達成合作,將有助於發揮各自在藥物研發、感染診斷領域的專長,以及在市場、渠道和服務上的優勢,更好地助力中國的艾滋病防控事業,對公司未來業務發展將產生積極促進作用,符合公司整體發展戰略規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.